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Prevalence of the TM6SF2 variant and non-alcoholic fatty
liver disease in Chinese
Letters to the EditorTo the Editor:
Non-alcoholic fatty liver disease (NAFLD) is currently the most
common chronic liver disease worldwide and may progress to
cirrhosis and hepatocellular carcinoma [1–3]. A recent exome-
wide association study identiﬁed the TM6SF2 variant (encoding
p.Glu167Lys) as a novel locus associated with higher liver fat
level [4]. The variant is associated with decreased hepatic secre-
tion of very-low-density lipoprotein and higher risk of myocar-
dial infarction [4,5].
Since Asians were underrepresented in the exome-wide asso-
ciation studies [4,5], here we report the prevalence of the TM6SF2
variant in a well-characterized Chinese cohort. In the HK-MRS
Study, 922 randomly selected community subjects underwent
non-invasive assessment of liver fat and ﬁbrosis by proton-
magnetic resonance spectroscopy and transient elastography,
respectively [3]. All subjects were ethnic Chinese. Genotyping
was performed using a TaqMan assay (dbSNP rs58542926;
Applied Biosystems, C_89463510_10) in 920 subjects with ade-
quate blood samples.
Overall, the TM6SF2 variant was detected in 4 subjects (0.4%,
95% CI 0–0.9%). Subjects carrying the variant had signiﬁcantly
lower total cholesterol and low density lipoprotein-cholesterol
levels than those without (Table 1). None of them were taking
lipid-lowering drugs at the time of assessment. Though limitedTable 1. Clinical characteristics of community Chinese subjects with different TM6
Characteristics EEa
n 794
Age (yr) 48 ± 11
Female sex, n (%) 455 (57.3)
Body mass index (kg/m2) 22.9 ± 3.5
Waist circumference (cm) 82 ± 10
Alanine aminotransferase (IU/L) 21 (17-31)
Aspartate aminotransferase (IU/L) 19 (17-23)
Fasting glucose (mmol/L) 5.1 ± 0.9
Total cholesterol (mmol/L) 5.2 ± 1.0
HDL-cholesterol (mmol/L) 1.5 ± 0.4
LDL-cholesterol (mmol/L) 3.0 ± 0.9
Triglycerides (mmol/L) 1.1 (0.8-1.7)
Diabetes, n (%) 31 (3.9)
Hypertension, n (%) 123 (15.5)
Intrahepatic triglyceride content (%) 2.1 (0.9-6.0)
Intrahepatic triglyceride content ≥5.0%, n (%) 222 (28.0)
Liver stiffness measurement (kPa)b 4.6 ± 1.7
Liver stiffness ≥9.6 kPa, n (%)b 11 (1.7)
Values are mean ± standard deviation or median (interquartile range), the latter for var
HDL, high density lipoprotein; LDL, low density lipoprotein.
aEE, homozygotes for the allele encoding Glu167; EK, heterozygotes; KK, homozygotes
bIncluding 758 subjects with valid and reliable liver stiffness measurement by transien
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Open access under CC BY-NC-ND license.by small numbers, subjects carrying the variant also tended to
have higher liver fat. Two of the 4 subjects had NAFLD with intra-
hepatic triglyceride contents of 13.9% and 21.1% suggestive of
moderate to severe steatosis. These 2 subjects were carrying
the GG and CG genotypes at the patatin-like phospholipase 3
gene (PNPLA3 rs738409, encoding p.Ile148Met), which is another
major genetic determinant of NAFLD [6]. On the other hand, none
of the subjects with the TM6SF2 variant had increased liver stiff-
ness measurement by transient elastography indicative of
advanced ﬁbrosis or cirrhosis [7]. Furthermore, TM6SF2 heterozy-
gotes did not have increased liver fat and ﬁbrosis compared to the
homozygotes for the allele encoding Glu167 (Table 1).
Our data suggest that the TM6SF2 variant is rare in the Chinese
population and probably does not cause severe liver injury from
NAFLD. The impact of this genetic variant at the population level
is thus limited. However, its discovery sheds light on the patho-
genesis of NAFLD and may unravel new treatment targets.
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EKa KKa p value
122 4
50 ± 11 39 ± 10 0.062
73 (59.8) 3 (75.0) 0.68
22.4 ± 3.5 21.5 ± 4.1 0.23
80 ± 10 80 ± 10 0.28
22 (16-27) 29 (13-49) 0.73
20 (16-23) 22 (15-27) 0.85
5.2 ± 0.8 5.1 ± 0.8 0.87
5.1 ± 1.2 3.6 ± 1.1 0.009
1.6 ± 0.4 1.2 ± 0.4 0.18
3.0 ± 1.0 2.0 ± 0.8 0.049
0.9 (0.7-1.2) 1.2 (0.4-1.7) 0.002
7 (5.8) 0 0.58
18 (14.8) 1 (25.0) 0.85
2.1 (0.9-6.0) 7.5 (0.8-19.3) 0.73
39 (32.0) 2 (50.0) 0.42
4.9 ± 1.8 4.7 ± 0.8 0.27
4 (4.3) 0 0.22
iables not following normal distribution.
for the allele encoding Lys167.
t elastography.
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Bacterial translocation in liver cirrhosis: Site and role
in ﬁbrogenesis
To the Editor:
I read with great interest the comprehensive review byWiest and
colleagues [1] on pathological bacterial translocation in liver
cirrhosis. They remarkably analyzed the compartments involved
and their inﬂuencing factors. My concern regards the possible
site(s) of bacterial translocation (BT), and the role of BT in the
progress of both precirrhotic chronic liver damage, particularly
ﬁbrosis, and installed liver cirrhotic lesions themselves.
Regarding the site of bacterial translocation in cirrhosis, the
authors rightly outline that, whereas small intestinal bacterial
overgrowth has the greatest potential for promoting BT and
bacteria causing spontaneous infections are most frequently
exactly those overgrowing in the small intestine [2,3], studies
of experimental liver injury in mice revealed that the cecum
and the colon might be the sites with largest rate of BT and
increase in intestinal permeability [1]. Data in humans were lack-
ing. A recent in vivo human study, not referenced in the Wiest’s
review [1], has reported that colonic permeability was increased
in patients with compensated liver cirrhosis, as compared to
matched controls using a multisugar test, whereas gastroduode-
nal and small intestine permeability were not altered [4].
Whether or not these changes preceded alterations of the gut
microbiome is not known.
A second point of increasing importance, not discussed in the
review [1], regards the experimental role of inﬂammasomes at
the colonic level in both local microbiota taxonomy and potential
translocation associated with chronic precirrhotic liver disease,
namely non-alcoholic fatty liver disease (NAFLD) and non-alco-
holic steatohepatitis (NASH). There is suggestive evidence that
a deﬁciency in components of two inﬂammasomes (NLRP6 and
NLRP3) – which are large multiprotein complexes that sense
intracellular danger signals via NOD-like receptors (NLRs), the
sensor, NLR, forming a complex with the effector molecule, pro-
caspase-1, with or without the contribution of an adapter mole-
cule, such as the apoptosis-associated speck like CARD-domain
containing protein (ASC) – normally acting as sensors of endoge-
nous or exogenous pathogen-associated molecular patterns
(PAMPs) and regulators of the colonic microbiota, leads to dysbi-
osis associated with aggravation of NAFLD and progression to
NASH [5]. Thus, members of the altered colonic microbiota in
inﬂammasome-deﬁcient mice may promote a signalling cascade
in the liver upon translocation, resulting in progression to NASH
in susceptible animals. Toll-like receptors (TLRs) have a major
role in NAFLD pathophysiology due to the liver’s exposure to rel-
atively large amounts of PAMPs derived from the intestine and
delivered via the portal circulation. Intact bacteria or bacterial
products derived from the intestine trigger TLR4 and TLR9 activa-
tion, which results in an increased rate of chronic liver disease
progression in mice that house a colitogenic gut microbiota asso-
ciated with inﬂammasome deﬁciency [5]. Indeed bacterial over-
growth, including in colon [7], is particularly important in
patients with a leaky gut because it increases the luminal amount
of PAMPs. It is noteworthy that mice deﬁcient in sensing PAMPs
or downstream signaling are resistant to NASH [6].
Finally, the consequences of intestinal dysbiosis or bacterial
overgrowth associated with gut leakage may not be limited to
infectious complications, as spontaneous bacterial peritonitis,
due to translocation. Animal studies have clearly pointed that
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